

- 1. This document was created to support maximum accessibility for all learners. If you would like to print a hard copy of this document, please follow the general instructions below to print multiple slides on a single page or in black and white.
- 2. This handout is for reference only. Non-essential images have been removed for your convenience. Any links included in the handout are current at the time of the live webinar, but are subject to change and may not be current at a later date.
- 3. Copyright: Images used in this course are used in compliance with copyright laws and where required, permission has been secured to use the images in this course. All use of these images outside of this course may be in violation of copyright laws and is strictly prohibited.
- 4. Social Workers: For additional information regarding standards and indicators for cultural competence, please review the NASW resource: <u>Standards and Indicators for Cultural Competence in Social Work</u>
 Practice
- 5. Need Help? Select the "Help" option in the member dashboard to access FAQs or contact us.

How to Print Handouts

- On a Mac
 - Open PDF in Preview
 - Click File
 - Click Print
 - Click dropdown menu on the right "preview"
 - Click layout
 - Choose # of pages per sheet from dropdown menu
 - Checkmark Black & White if wanted.

- On a PC
 - Open PDF
 - Click Print
 - Choose # of pages per sheet from dropdown menu
 - Choose Black and White from "Color" dropdown

No part of the materials available through the continued.com site may be copied, photocopied, reproduced, translated or reduced to any electronic medium or machine-readable form, in whole or in part, without prior written consent of continued.com, LLC. Any other reproduction in any form without such written permission is prohibited. All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of continued.com, LLC. Users must not access or use for any commercial purposes any part of the site or any services or materials available through the site.



cCMV: Essential Knowledge for Audiologists



Deborah Flynn, AuD Alissa Nickerson, AuD Wendy Steuerwald, AuD









Deborah Flynn, AuD



Deborah Flynn is the Audiology Lead for Cochlear Implants at Phoenix Children's Hospital. She has extensive experience in identification, intervention, and management of infants, children, and teens with hearing loss.







Alissa Nickerson, AuD



Alissa Nickerson is a clinical audiologist at Phoenix Children's specializing in the diagnosis and management of childhood hearing loss.







Wendy Steuerwald, AuD



Wendy Steuerwald is the Director of Audiology at Phoenix Children's. She works with audiologists to create protocols and an environment where exceptional patient care is provided.







Disclosures

- Presenter Disclosure: Financial: Deborah Flynn is employed by Phoenix Children's Hospital. Non-financial: Deborah Flynn has no relevant non-financial relationships to disclose. Financial: Alissa Nickerson is employed by Phoenix Children's Hospital. Non-financial: Alissa Nickerson has no relevant non-financial relationships to disclose. Financial: Wendy Steuerwald is employed by Phoenix Children's Hospital. Non-financial: Wendy Steuerwald has no relevant non-financial relationships to disclose. In lieu of accepting an honorarium, a donation has been made to the Ear Foundation of AZ.
- Content Disclosure: This learning event does not focus exclusively on any specific product or service.
- Sponsor Disclosure: This course is presented in partnership with Midwestern University and Phoenix Children's Hospital.
- This course is based on review of literature, information gained from a cCMV survey conducted in AZ and clinic experience with cCMV.







Learning Outcomes

After this course, participants will be able to:

- Explain the difference between symptomatic and asymptomatic cCMV.
- List three ways to reduce transmission of CMV.
- Explain the audiologic management for patients with cCMV.





Proclamation

WHEREAS, congenital cytomegalovirus (CMV) is the most common congenital infection in the United States with about 1 in 200 children born with congenital CMV; and

WHEREAS, congenital CMV is the most common cause of birth defects in childhood disabilities in the United States, and 40 to 60 percent of infants born with signs of congenital CMV disease at birth will have long-term health problems; and

WHEREAS, congenital CMV is preventable with simple behavioral interventions while pregnant, such as practicing frequent hand washing with soap and water after contact with diapers and oral secretions, not kissing young children on the mouth, and not sharing utensils with young children; and WHEREAS, most people are not aware of their CMV infection status, with pregnant women being one of the highest risk groups; and

WHEREAS, CMV infection is more common that the combined metabolic or endocrine disorders currently in the United States core newborn screening panel; and

WHEREAS, the incidence of children born with congenital CMV can be greatly reduced with public education and awareness.

NOW, THEREFORE, I, Katie Hobbs, Governor of the State of Arizona, do hereby proclaim June 2023 as

ARIZONA CMV AWARENESS MONTH



IN WITNESS WHEREOF, I have hereunto set my hand and caused to be affixed the Great Seal of the State of Arizona

GOVERNOR

DONE at the Capitol in Phoenix on this twenty-fifth day of May in the year Two Thousand and Twenty-Three, and of the Independence of the United States of America the Two Hundred and Forty-Seventh.

ATTE.

SECRETARY OF STAT







What is Cytomegalovirus (CMV)?

- CMV is a common herpes virus.
- It is typically harmless when acquired by children or adults. (1)
- CMV is common in children, especially those in day care







What is Congenital Cytomegalovirus (cCMV)?

- (cCMV) is CMV which is acquired by the infant while in utero.⁽¹⁾
- cCMV is the "most common infectious cause of birth defects in the United States," impacting 1 of every 200 births.⁽¹⁾
- It is the leading cause of non-genetic, childhood-onset sensorineural hearing loss.
- Infants with cCMV can be symptomatic or asymptomatic.
- Cytomegalovirus (CMV) testing is recommended to be performed before the child is 21 days old to differentiate CMV from cCMV.







cCMV is Complicated by a Variety of Factors, Including:

Lack of community and medical awareness

Kathleen Muldoon cCMV researcher (CMV 101)

AAA Position statement. Maggie Kettler lead author

Stop CMV AZ/Alto CMV AZ. National CMV Foundation

State Proclamations cCMV awareness month

State Legislation

Utah public awareness program (Congenital CMV: Advocacy and Legislation)

SENTAC, ACIA, Audiology On Line







cCMV is Complicated by a Variety of Factors, Including:

Lack of universal screening

Variation in ways to screen, differences in sensitivity of screening methods, variation in models of who to screen, differences in lab assays. Blood spot used in future

Lack of agreement on treatment for mother during pregnancy (Pathophysiology Diagnosis &Treatment)

- Inconsistent presentation: symptomatic or asymptomatic
 St. Joe's Phoenix study (Hearing Loss in cCMV)
- Range of severity







Symptomatic vs Asymptomatic

- 90% of babies with cCMV present asymptomatically.⁽³⁾
 - These children generally follow typical developmental patterns but may experience minor developmental challenges as they age.
- 10% of babies with cCMV present with symptoms
- An infant is considered symptomatic if they exhibit one or more clinical signs or related conditions. This may include, but is not limited to: (3, 4, 8).

•	Rash	Hearing loss	Seizures
•	Vision problems	Jaundice	Failure to Thrive
•	Cognitive delays purpura	Microcephaly	Petechiae and/ or
•	Feeding difficulties	Small for gestational age	
	Cerebral palsy	IUGR	
•	Problems with muscle tone	Hepatosplenomegaly	

(enlarged liver & spleen)

 Because many infants are asymptomatic at birth, and CMV is not universally screened for in the US, cCMV infections can go undiagnosed.⁽⁹⁾

Retinitis







Precautions for Health Care Providers, including Audiologists

 No vaccine publicly available for CMV. Vaccines are in development. Clinical trials are occurring (2)

Moderna <u>www.cmvictory</u>. Merck

- Shedding of the virus can occur with or without signs or symptoms.⁽¹¹⁾
- Adults shed the virus for less duration compared to children, typically <6 months. (11)
- People who are in close contact to children under two years old are especially susceptible for contracting CMV as the virus can be released in saliva and urine for years. (2)
 - At 18 months of age, a study demonstrated that all children with cCMV exhibited virus shedding in urine. In these same children, only 24% demonstrate shedding in saliva.⁽⁵⁾
 - Shedding peaks at 1-2 years of age, suggesting that very young children pose a risk of transmission to pregnant women.⁽⁶⁾
- Contact precautions are recommended for health care workers exposed to CMV.⁽⁸⁾







How to Reduce Risk of CMV Infection

- Saliva contact is the most likely route of transmission for pregnant women.⁽⁸⁾
- Do not share anything with a child that goes in their mouth. This includes toothbrushes, drinks, food, and utensils.⁽⁷⁾
 - "I get my own cup."
- Do not put a child's pacifier in your mouth.⁽⁷⁾
- Avoid contact with saliva when kissing a child.⁽⁷⁾
- Wash your hands often, using soap and water. (2,7)
- Thinking about the audiology clinic...
 - Clean toys, countertops and other clinic areas that may come in contact with a child's saliva, drool, mucous, or urine after the child departs.
 - CMV can live on plastics for 15 minutes.
 - Disinfect equipment and furniture.
 - Use disposable equipment when available.
 - If child sneezes on the tissue box, or anything that can't be cleaned, give it to them or throw away.







Audiologic Considerations for cCMV+ Infants

- Symptomatic children are more likely to have HL compared to asymptomatic children
 - 22-65% of symptomatic
 - 6-23% asymptomatic⁽¹⁸⁾
- Hearing loss can be unilateral, bilateral, early-onset, late-onset and/or progressive.
- Late onset hearing loss occurs 30-50% of cases.⁽¹²⁾
- Increasing severity of hearing loss with increasing age, as progression of hearing loss is common. (13).
- Newborn hearing screening programs will not detect all cCMV+ infants who will develop hearing loss.⁽¹³⁾
 - In fact, it may detect less than half of cCMV-related hearing loss.⁽¹⁴⁾
 - Hearing loss has been identified as early as 3 months for infants who passed the NBHS within the first month of life.







Audiologic Testing Schedule for cCMV+ Patients

Multiple testing schedules suggested:

- Testing every 3 months until age 3, then biannually until age 6, and then annually
- Testing every 3-6 months for the first year of life, then biannually until age 3, then annually until age 6
- Testing at age 3 months, then annually until age 4
- AAA recommends Model 2 (12)
 - Goal is to identify hearing loss during the ages in which cCMV+ children are most at-risk⁽¹²⁾
 - Early interventions can be initiated⁽¹²⁾
 - Consider interventions which are flexible to account for possible progressive HL⁽¹²⁾







Special Considerations for Audiologic Assessment

- Rapid progression of hearing loss is common. (12)
 - How does that impact our assessment?
 - How does that impact our treatment selections?
 - HA flexible to accommodate?
 - Possible CI in future?
- Symptomatic infants are more likely to have severe sequelae.
 - Multidisciplinary approach.
 - Developmental abilities may impact assessment.
- cCMV can impact vision
 - Dual sensory impairment possible.^(8,12)
 - How should that impact our assessment (i.e. VRA?)
- cCMV can impact vestibular system.⁽¹⁹⁾
 - Can be variable similar to HL⁽¹⁹⁾
 - Can be impacted in patients with normal hearing⁽¹⁹⁾
 - Vestibular evaluations should be considered for cCMV+ patients⁽¹⁹⁾







Audiologic Findings from Cohort of 15 CMV+ Patients at Phoenix Children's Audiology Dept.

Take-Aways:

- Most exhibited hearing loss
- Almost half in this cohort developed severe or profound hearing loss in at least one ear
- Despite this, only 20% of these patients were identified as having hearing loss within the first month of life. This highlights the need for routine surveillance of these CMV+ patients

Hearing loss	14 Hearing Loss
Laterality	8 Bilateral, 6 Unilateral
Type (right)	14 SNHL
Type (left)	13 SNHL, 1 Mixed
Degree (right)	3/15: Normal 2/15: Mild 3/15: Moderate 7/15: Severe and/or Profound
Degree (left)	5/15: Normal 4/15: Mild 2/15: Moderate 4/15: Severe and/or Profound
Age at cCMV Dx	1/15: In Utero 3/15: Within first week after birth 3/15: 8-51 days after birth 8/15: Unknown (i.e. transfer patient, records not available)
Age at HL Dx	1/15: No Hearing Loss 3/15: <1 month 3/15: 1-3 months 3/15: 3-6 months 2/15: 1-3 years 2/15: >3 years of age 1/15: Unknown







Audiologic Interventions


- Hearing Aid(s): When hearing loss is sufficient to warrant intervention
- Cochlear Implant(s): Severe to profound SNHL
- Bone Conduction Hearing Aid (BAHA): For CMV, typical use would be for Single sided deafness (SSD)
- FM system / Assistive technology







Prevalence of cCMV



(21) & (15)







Case studies to include:

- Range of ages
- Differing types and degrees of hearing loss
- Various treatment options







Case Study 1

- Case 1 (F.L.) 8-year-3-month old female
- History: cCMV, NICU stay 3 months, passed newborn hearing screen, developed speech/lang. age appropriately, passed school screening in kindergarten, parent/teacher concern 1st grade.
- Miscellaneous: Lives in a rural area
- Audiological history: Referred to rural ENT and dx with bilateral HL (10-2021), however, provider did not specialize in pediatrics. Fit temporarily with a RIC hearing aid with dome and transferred care to Phoenix Children's. Tested and found to have profound hearing loss in left ear and severe rising to moderately/severe SNHL in the right ear (1-2022).








Initial Diagnosis

AUDIOGRAM

Frequency in Hz



SPEECH AUDIOMETRY

	PTA	SRT	HL/SL %	HL/SL %	Materials
Right Ear	dB	dB	105 68		WIPF
Left Ear	dB	dB	CAST		WEPI
Sound Field	dB	dB			

KEY TO SYMBOLS

	MOD 11 (TD)	EAR					
٠	MODALITY	RIG	нт	[UNSPE	ECIFIED]	U	EFT
	AIR-CONDUCTION UNMASKED		5			>	k
	MASKED	1	7				
	BONE-CONDUCTION						
	UNMASKED	\leq			i		>
	MASKED	Ľ					
	SOUNDFIELD						
	UNAIDED	:		9	6		
	AIDED			A	Ā		
	COCHLEAR IMPLANT			(P		
	NO RESPONSE	1					7

Audiometric Techniques
Conventional
Conditioned Play
Visual Reinforcement
Behavioral Observation
Transducers
Transducers
Test Signals
Pure Tones
Warble Tones
Monitored Live-Voice
Recorded Speech

TDH Headphones

TYMPANOGRAM









Treatment

- Fit with BTE hearing aids and evaluated for CI in left ear.
- Implanted in left ear 5-17-2022; made good progress with CI.
- Had open-set speech within 2 months.
- Returned for CI f-up 7-15-2022 and hearing dropped in right ear (better ear) to severe sloping to profound.
 Discrimination dropped from 68% to 24%.









Progression


Evaluate for second CI



AUDIOGRAM

KEY TO SYMBOLS












Conformation of Progression









Treatment

- Evaluated for second CI
- There was some concern about implanting the right ear
 - F.L. has been dependent on this ear
 - Just started another school year
 - Family lives 6 hour round trip from the hospital
 - Just completed activation series of first ear
 - Only been implanted on the other side 4 months ago
- Family decided to proceed with implant
- Right ear implanted on 9-13-2022








Aided benefit with CI

- Implanted in right ear 9-2022
- Testing completed 2-2023
- s/p second CI (5 months)



AUDIOGRAM

Frequency in Hz



HINT (quiet) 50dB= 100% AZ Bio= +10 (50/40dB)=93% +5 (50/45dB)=91%

Tympanimetry/immittance Results:

liste	-	-their ton-	Values (Admittance (reached)	Pest Pressure (daPs)	Tympani Walls	Tymporen Type
03-06-2023	Right EAL	775 Hz	8.67	0.10	-31	7	rei A
02-06-2023	Left Edu	72FHz	0.51	0.21	451	7	riper C








Aided Benefit

AUDIOGRAM

Frequency in Hz




SPEECH AUDIOMETRY

[PTA	SAT	HL/SL %	HL/SL %	Materials
Right Ear	dB	dΒ			
Left Ear	dB	dB			
Sound Field	dB	σВ	52		

AUDIOGRAM

Frequency in Hz



SPEECH AUDIOMETRY

	PTA	SRT	HL/SL %	HL/SL %	Materials
Right Ear	dB	dB			
Left Ear	dB	₫B			
Sound Field	dB	dВ	10 12		







Case Study 2


- E.K. a 3-year-old male
- Medical history includes perinatal history of cardiac arrest at birth, HIE (hypoxic ischemic encephalopathy) in basal ganglia area which controls movement of muscles, due to GBS sepsis, neonatal seizures, conjugated hyperbilirubinemia-obstruction of biliary tract resulting in inability of bilirubin to move into the intestines, CMV infection.
- Failed newborn hearing screening. Seen for dx testing at 21 days and found to have bilateral ANSD.
- Grossly abnormal waveform morphology







ABR Study









Treatment

He has been monitored over time.


- Most recent audiogram, which was last month indicated:
 - Mild hearing loss in the left ear
 - Moderate hearing loss in the right ear
 - With Type A tympanograms
 - Absent acoustic reflexes








Behavioral Testing











Treatment Plan

- He does not currently wear hearing aids, but HA trial recommended for at least the right ear.
- Responds to parents and environmental sounds.
- Speech: Parent report that speech and language is developing well overall except for some articulation errors. He receives regular therapies including physical and occupational therapies.
- Audiological Monitoring every 6 months now that he is three years of age.







Case Study 3


- A.S. is a 5-year-old female
- Hx: full-term, healthy pregnancy but dx cCMV
- NBHS: passed L, failed R on 1st attempt, passed both on 2nd attempt
- Due to cCMV-referred for dx BAER at 13 days
- BAER-mild S/N HL (right ear); essentially normal (left ear) with OAEs absent in the right ear and present in the left ear.








First Diagnostic Evaluation











Follow up Testing


- A.S. did not return for one year.
- Behavioral testing could not rule out hearing loss and a BAER study was recommended.
- F-up BAER/OAE/Tymps study revealed:
 - Essentially normal hearing in the left ear
 - Severe/profound sensorineural hearing loss in the right ear










1 Year Later















Treatment

- Treatment options were discussed with the family (BAHA/CROS). Due to age (15 months), BAHA was selected. CI not an option at the time; FDA had not approved for SSD.
- A.S. successfully wore softband BAHA for several years and attended an Oral Learning School.
- She returned for routine audiological monitoring and is now >5 yrs.
- Family decided to purse CI for the right ear.
- Undergoing work up and will be implanted this month.







Case Study 4


- K.B. is a 6-year-3-month old male with a complex medical hx which includes bilateral hearing loss, global developmental delay, cCMV and autism spectrum disorder.
- Moved from FL to AZ. Hx of bilateral otitis media with several sets of tympanostomy tubes.
- Failed a newborn hearing screening in both ears. Dx with bilateral hearing loss in both ears, greater in the right than in the left ear. Right ear hearing loss progressive.
- Had a hearing aid in the right ear only.
- His initial BAER study in AZ indicated moderate rising to mild conductive hearing loss in the left ear and a profound sensorineural hearing loss in the right ear.
- He is followed by an outside neurotologist.








Dx: In AZ at 4-years-1-month





Left- PE tube removed, TM perforation remaining

Right-type A tympanogram







Management Plan


- Following BAER results:
 - Left ear fit with hearing aid
 - Right ear work up for cochlear implant
- Family decided to pursue a CI, deemed CI candidate given history of cCMV and progressive hearing loss
- Implanted in the right ear 8-2021










Testing from 1 year post CI activation


















Follow-up testing



SPEECH AUDIOMETRY



Sensorineural hearing loss has since developed in the left ear Monitor every 6 months or sooner if concerns arise



Right Ear		Left Ear
1.3	Earcanal (mmhos)	67
259	Static Admittance (mmhos)	0,83
0776	Peak Pressure (daPa)	-12







Audiological Treatment Considerations

- Consider use of a flexible hearing aid given that progressive hearing loss is prevalent
- Consider Cochlear Implants given new ACIA guidelines for children
- Consider BAHA/CROS hearing aid for those not interested in a surgical option







CI Candidacy (20)


Audiometric Thresholds >70dBHL

Word Recognition ≤50%

Poor functional performance

Limited Progress

Poor Quality of Life









Take Home Message

- Most states do not have universal cCMV screening at this time
- Most of the patients described were identified due to a comorbid condition
- We are currently conducting a small-scale study to determine feasibility of CMV testing in hopes of working toward state-wide screening
- Working on community awareness "Stop CMV AZ"
- Governor just signed a proclamation making June AZ cCMV awareness month







Thank you!

Deborah Flynn, AuD Alissa Nickerson, AuD Wendy Steuerwald, Au.D., CCC-A

Questions?

Wendy Steuerwald, Au.D., CCC-A
Director of Audiology
Phoenix Children's Hospital

wsteuerwald@phoenixchildrens.com









References

- (1) Center for Disease Control and Prevention. (2022). Babies Born with Congenital CMV. https://www.cdc.gov/cmv/congenital-infection.html
- (2) Rawlinson, W.D., Boppana, S.B., Fowler, K.B., Kimberlin, D.W., Lazzarotto, T., Alain, S., ... van Zuylen, W.J. (2017). Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infectious Disease. 17(6):e177-e188. https://pubmed.ncbi.nlm.nih.gov/28291720/
- National CMV Foundation. (2023). Potential Outcomes of Congenital CMV. https://www.nationalcmv.org/overview/outcomes#:~:text=Symptomatic%20at%20Birth,an%20enlarged%20liver%20or%20spleen
- (4) Center for Disease Control and Prevention. (2018). Congenital CMV and Hearing Loss. https://www.cdc.gov/cmv/downloads/2018-cmv-hearing-fact-sheet-7b-508.pdf
- Puhakka, L., Pati, S., Lappalainen, M., Lönnqvist, T., Niemensivu, R., Lindahl, P., Saxen, H. (2020). Viral shedding, and distribution of cytomegalovirus glycoprotein H (UL75), glycoprotein B (UL55), and glycoprotein N (UL73) genotypes in congenital cytomegalovirus infection. Journal of Clinical Virology, 125. https://www.sciencedirect.com/science/article/pii/S1386653220300299?via%3Dihub#bib0015
- (6) Cannon, M.J., Hyde, T.B., & Schmid, D.S. (2011). Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection. Medical Virology, 21(4), 240-255.
- (7) National CMV Foundation (2023). CMV Prevention and Healthy Pregnancy Tips. https://www.nationalcmv.org/overview/prevention-tips
- (8) Dedhia, K., Fifer, R.C., Muldoon, K.M., & Park, A. (2021). A Cross-sectional Survey Evaluating Awareness of Congenital Cytomegalovirus Among Audiologists and Speech Language Pathologists. American Journal of Audiology, (30)1, 145-159. https://doi.org/10.1044/2020_AJA-20-00167
- (9) Schleiss, M. R. (2018). Congenital cytomegalovirus: Impact on child health. Contemporary Pediatrics, 35(7), 16–24.
- Castillo, K., Hawkins-Villarreal, A.H., Valdes-Bango, M., Guirado, L., Scazzocchio, E. Porta, O. ... Gonce, A. (2021). Congenital Cytomegalovirus Awareness and Knowledge among Health Professionals and Pregnant Women: An Action Towards Prevention. Fetal Diagnosis and Therapy (49)265-272. https://www.karger.com/Article/Pdf/525528







References

- (11) Oklahoma State Department of Health. (2014). Cytomegalovirus. https://oklahoma.gov/content/dam/ok/en/health/health/documents/cytomegalovirus.2014.pdf
- (12) Kettler, M., Shoup, A., Moats, S., Steuerwald, W., Jones, S., Stiell, S. C., & Chappetto, J. (2023). American Academy of Audiology Position Statement on Early Identification of Cytomegalovirus in Newborns. Journal of the American Academy of Audiology.
- (13) Lanzieri, T.M, Chung, W., Flores, M., Blum, P., Caviness, A.C., Bialek, S.R. ... & Demmler-Harrison, G. (2017) Hearing Loss in Children With Asymptomatic Congenital Cytomegalovirus Infection. Pediatrics, 139(3). https://pubmed.ncbi.nlm.nih.gov/28209771/
- (14) Fowler, K.B., Dahle, A.J., Boppana, S.B., & Pass, R.F. (1999). Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed? Journal of Pediatrics, 135(1):60–64
- (15) Fowler, K. B. (2013). Congenital cytomegalovirus infection: Audiologic outcome. Clinical Infectious Diseases, 57(Suppl. 4), S182–S184. https://doi.org/10.1093/cid/cit609
- (16) Fowler, K. B., & Boppana, S. B. (2018). Congenital cytomegalovirus infection. Seminars in Perinatology, 42(3), 149–154. https://doi.org/10.1053/j.semperi.2018.02.002
- (17) Vauloup-Fellous, C., Picone, O., Cordier, A.G., Parent-du-Châtelet, I., Senat, M.V., Frydman, R., ... & Grangeot-Keros, L. (2009). Does hygiene counseling have an impact on the rate of CMV primary infection during pregnancy? Results of a 3-year prospective study in a French hospital. Journal of Clinical Virology, 46(Suppl 4):S49-53.
- (18) Fowler, K.B., Boppana, S.B. (2006). Congenital CMV infection and hearing deficit. Journal of Clinical Virology, 35, 226-31.
- (19) Dhondt, C., Maes, L., Rombaut, L., Martens, S., Vanaudenaerde, S., Van Hoecke, H. ... Dhooge, I. (2021). Vestibular Function in Children With a Congenital Cytomegalovirus Infection: 3 Years of Follow-Up. Ear & Hearing, 42(1), 76-86. https://pubmed.ncbi.nlm.nih.gov/32590628/







References

- (20) Warner-Czyz, Andrea D.1; Roland, J. Thomas Jr2; Thomas, Denise3; Uhler, Kristin4,5; Zombek, Lindsay6. American Cochlear Implant Alliance Task Force Guidelines for Determining Cochlear Implant Candidacy in Children. Ear and Hearing 43(2):p 268-282, March/April 2022. | DOI: 10.1097/AUD.0000000000001087
- (21) Lanzieri TM, Chung W, Flores M, Blum P, Caviness AC, Bialek SR, Grosse SD, Miller JA, Demmler-Harrison G; Congenital Cytomegalovirus Longitudinal Study Group. Hearing Loss in Children With Asymptomatic Congenital Cytomegalovirus Infection. 24 Pediatrics. 2017 Mar;139(3):e20162610. doi: 10.1542/peds.2016-2610. Epub 2017 Feb 16. PMID: 28209771; PMCID: PMC5330400.